1. Home
  2. CR vs CYTK Comparison

CR vs CYTK Comparison

Compare CR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crane Company

CR

Crane Company

HOLD

Current Price

$222.36

Market Cap

10.7B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$85.69

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CR
CYTK
Founded
1855
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
10.7B
IPO Year
2022
2004

Fundamental Metrics

Financial Performance
Metric
CR
CYTK
Price
$222.36
$85.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
19
Target Price
$226.20
$89.26
AVG Volume (30 Days)
469.7K
2.1M
Earning Date
04-27-2026
05-05-2026
Dividend Yield
0.58%
N/A
EPS Growth
23.96
N/A
EPS
1.14
N/A
Revenue
$2,305,000,000.00
$13,368,000.00
Revenue This Year
$27.98
$7.37
Revenue Next Year
$5.76
$310.19
P/E Ratio
$193.41
N/A
Revenue Growth
8.16
N/A
52 Week Low
$159.58
$32.89
52 Week High
$226.46
$87.33

Technical Indicators

Market Signals
Indicator
CR
CYTK
Relative Strength Index (RSI) 73.41 69.90
Support Level $173.83 $59.07
Resistance Level N/A N/A
Average True Range (ATR) 6.31 3.16
MACD 1.12 1.24
Stochastic Oscillator 86.09 86.99

Price Performance

Historical Comparison
CR
CYTK

About CR Crane Company

Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: